News

Read our white paper on the clinical development challenges in oncology

 Optimising Early Clinical Development Strategies in Oncology According to the largest analysis of almost 7,500 clinical and regulatory phase transitions, the likelihood of an oncology drug progressing from Phase I clinical testing is 5%, the lowest of the 14 major…

Read more >
July 31 2020 0 comments

Proud to be part of the ATTC Network

The Advanced Therapy Treatment Centre Industry Advisory Group brings together 39 leading companies, including Aptus Clinical, who work collaboratively with the NHS to navigate common challenges and support routine clinical adoption of advanced therapies in the UK. https://www.theattcnetwork.co.uk/case_studies/industry-involvement-in-the-attc-programme

Read more >
July 14 2020 0 comments

Covid-19 update

In light of updated UK government advice, we have decided to trigger our business continuity plan which focuses on keeping our staff safe by working from home whilst continuing to deliver projects supported through virtual ways of working. Remote working…

Read more >
March 18 2020 0 comments

Aptus Clinical and Alderley Park benefit from Northern Powerhouse Investment Fund

The Northern Powerhouse Investment Fund which is delivered by British Business Bank, has invested a total of £2.5m into businesses based at Alderley Park, Cheshire, the UK’s largest single site life science campus. The £2.5m invested into businesses at Alderley…

Read more >
February 24 2020 0 comments

Renaissance of interest in medicines modulating ECS: Rising to the challenge

Steve McConchie, CEO at Aptus Clinical shares his analysis on cannabinoid medicines, with Andy Yates of Artelo Biosciences, in Pharmafile. The body’s endocannabinoid system (ECS) consists of receptors and chemical messengers located in the central and peripheral nervous system, forming…

Read more >
December 13 2019 0 comments

Aptus Clinical selected as clinical CRO by Artelo Biosciences

Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd.) to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on…

Read more >
November 19 2019 0 comments

Aptus Clinical is a very supportive workplace, keen on developing people

We say goodbye to Anitah who has now come to the end of her one year work placement with us. Here is what she had to say:   As we draw near to my final day here at Aptus I…

Read more >
October 25 2019 0 comments

Aptus Clinical launches a full Clinical Data Management Service, thanks to iMATCH

Innovate UK funding spurs growth in iMATCH companies As a result of their involvement in the iMATCH Project, Aptus Clinical are now able to offer a full Clinical Data Management service, offering a wide range of services from eCRF Design,…

Read more >
September 18 2019 0 comments

North takes on South in UK’s life science industry – Financial Times

Aptus Clinical is proud to be mentioned in this article from todays FT –https://www.ft.com/content/e63b6006-9cdb-11e9-b8ce-8b459ed04726 When Ruth Roberts heard that AstraZeneca, where she had worked for a decade, was leaving its home at Alderley Park in Cheshire for a new headquarters…

Read more >
July 29 2019 0 comments

Aptus Clinical signs consulting contract with ValiRx plc

ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company’s clinical team has signed an agreement to work with Aptus Clinical Ltd (“Aptus”), the UK based, clinical Contract Research Organisation (“CRO”), to effectuate a…

Read more >
July 5 2019 0 comments